Cervarix®: a bivalent vaccine against HPV types 16 and 18, with cross-protection against other high-risk HPV types
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cervarix®: a bivalent vaccine against HPV types 16 and 18, with cross-protection against other high-risk HPV types
Authors
Keywords
-
Journal
Expert Review of Vaccines
Volume 11, Issue 6, Pages 645-657
Publisher
Informa UK Limited
Online
2012-08-08
DOI
10.1586/erv.12.42
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cervarix™, the GSK HPV-16/HPV-18 AS04-adjuvanted cervical cancer vaccine, demonstrates stability upon long-term storage and under simulated cold chain break conditions
- (2014) David Le Tallec et al. Human vaccines & immunotherapeutics
- School nurses' experiences of delivering the UK HPV vaccination programme in its first year
- (2011) Shona Hilton et al. BMC INFECTIOUS DISEASES
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Incident Cervical HPV Infections in Young Women: Transition Probabilities for CIN and Infection Clearance
- (2011) R. P. Insinga et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Human papillomavirus: science and technologies for the elimination of cervical cancer
- (2011) F Xavier Bosch EXPERT OPINION ON PHARMACOTHERAPY
- Primary prophylactic human papillomavirus vaccination programs: future perspective on global impact
- (2011) Julia ML Brotherton et al. Expert Review of Anti-Infective Therapy
- Cost–consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: The potential impact of different cross-protection profiles
- (2011) S. Capri et al. GYNECOLOGIC ONCOLOGY
- Correlation between levels of human papillomavirus (HPV)-16 and 18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with the HPV-16/18 AS04-adjuvanted vaccine
- (2011) Tino F. Schwarz et al. Human vaccines & immunotherapeutics
- The humoral response to Gardasil over four years as defined by Total IgG and competitive Luminex immunoassay
- (2011) Darron R. Brown et al. Human vaccines & immunotherapeutics
- Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose schedule
- (2011) Barbara Romanowski et al. Human vaccines & immunotherapeutics
- Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18
- (2011) A. Szarewski et al. INTERNATIONAL JOURNAL OF CANCER
- Population Effectiveness, Not Efficacy, Should Decide Who Gets Vaccinated Against Human Papillomavirus via Publicly Funded Programs
- (2011) P. E. Castle et al. JOURNAL OF INFECTIOUS DISEASES
- Incremental Impact of Adding Boys to Current Human Papillomavirus Vaccination Programs: Role of Herd Immunity
- (2011) Marc Brisson et al. JOURNAL OF INFECTIOUS DISEASES
- Just implementation of human papillomavirus vaccination
- (2011) Erik Malmqvist et al. JOURNAL OF MEDICAL ETHICS
- Proof-of-Principle Evaluation of the Efficacy of Fewer Than Three Doses of a Bivalent HPV16/18 Vaccine
- (2011) Aimée R. Kreimer et al. JNCI-Journal of the National Cancer Institute
- Human Papillomavirus Testing in the Prevention of Cervical Cancer
- (2011) Mark Schiffman et al. JNCI-Journal of the National Cancer Institute
- A new approach to cervical screening
- (2011) Chris JLM Meijer et al. LANCET ONCOLOGY
- Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial
- (2011) Aimée R Kreimer et al. LANCET ONCOLOGY
- Success of HPV vaccination is now a matter of coverage
- (2011) Mark Schiffman et al. LANCET ONCOLOGY
- Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
- (2011) Matti Lehtinen et al. LANCET ONCOLOGY
- Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
- (2011) Cosette M Wheeler et al. LANCET ONCOLOGY
- Weighing the Benefits and Costs of HPV Vaccination of Young Men
- (2011) Jane J. Kim NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males
- (2011) Anna R. Giuliano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunogenicity and Safety of Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine Administered According to an Alternative Dosing Schedule Compared With the Standard Dosing Schedule in Healthy Women Aged 15 to 25 Years
- (2011) Susanna Esposito et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Human papillomaviruses (HPV) vaccines: implementation and communication issues
- (2011) M. A. Kane JOURNAL OF FAMILY PLANNING AND REPRODUCTIVE HEALTH CARE
- HPV vaccine: Cervarix
- (2010) Anne Szarewski EXPERT OPINION ON BIOLOGICAL THERAPY
- Pathology and epidemiology of HPV infection in females
- (2010) Margaret Stanley GYNECOLOGIC ONCOLOGY
- Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: A pooled analysis of 11 clinical trials
- (2010) Dominique Descamps et al. Human vaccines & immunotherapeutics
- Comparison of the immunogenicity and safety ofCervarix™ andGardasil®human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years
- (2010) Mark H. Einstein et al. Human vaccines & immunotherapeutics
- Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-adjuvanted vaccine in preteen/adolescent girls and young women
- (2010) Tiina Petäjä et al. INTERNATIONAL JOURNAL OF CANCER
- Safety and Immunogenicity of the HPV-16/18 AS04-Adjuvanted Vaccine: A Randomized, Controlled Trial in Adolescent Girls
- (2010) Doris M. Rivera Medina et al. JOURNAL OF ADOLESCENT HEALTH
- Safety and Immunogenicity of the Quadrivalent Human Papillomavirus Vaccine in HIV‐1–Infected Men
- (2010) Timothy Wilkin et al. JOURNAL OF INFECTIOUS DISEASES
- Epidemiological Study of Anti-HPV16/18 Seropositivity and Subsequent Risk of HPV16 and -18 Infections
- (2010) M. Safaeian et al. JNCI-Journal of the National Cancer Institute
- Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data
- (2010) Basil Donovan et al. LANCET INFECTIOUS DISEASES
- Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study
- (2010) Silvia de Sanjose et al. LANCET ONCOLOGY
- Human Papillomavirus Infection and Cervical Disease in Human Immunodeficiency Virus-1–Infected Women
- (2010) Lynette Denny et al. OBSTETRICS AND GYNECOLOGY
- Post-licensure monitoring of HPV vaccine in the United States
- (2010) Lauri E. Markowitz et al. VACCINE
- The "Jade Goody effect": what now for cervical cancer prevention?
- (2010) Julie Bowring et al. JOURNAL OF FAMILY PLANNING AND REPRODUCTIVE HEALTH CARE
- The challenges of organising cervical screening programmes in the 15 old member states of the European Union
- (2009) Marc Arbyn et al. EUROPEAN JOURNAL OF CANCER
- Raising awareness of human papillomavirus and cervical cancer prevention: the need for clinical education
- (2009) Anne Szarewski Future Virology
- HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives
- (2009) Xavier Castellsagué et al. GYNECOLOGIC ONCOLOGY
- Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: Modeling of sustained antibody responses☆
- (2009) Marie-Pierre David et al. GYNECOLOGIC ONCOLOGY
- Postlicensure Safety Surveillance for Quadrivalent Human Papillomavirus Recombinant Vaccine
- (2009) Barbara A. Slade JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Sexually Active Women Aged 16–26 Years
- (2009) Cosette M. Wheeler et al. JOURNAL OF INFECTIOUS DISEASES
- Immunogenicity Testing in Human Papillomavirus Virus‐Like‐Particle Vaccine Trials
- (2009) John T. Schiller et al. JOURNAL OF INFECTIOUS DISEASES
- The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV‐Naive Women Aged 16–26 Years
- (2009) Darron R. Brown et al. JOURNAL OF INFECTIOUS DISEASES
- Human Papillomavirus Genotype Distributions: Implications for Vaccination and Cancer Screening in the United States
- (2009) Cosette M. Wheeler et al. JNCI-Journal of the National Cancer Institute
- Appropriate human papillomavirus vaccination strategies – Authors' reply
- (2009) Karin B Michels et al. LANCET
- HPV vaccine for all
- (2009) Karin B Michels et al. LANCET
- Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial
- (2009) Nubia Muñoz et al. LANCET
- Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women
- (2009) J Paavonen et al. LANCET
- Booster Vaccinations: Can Immunologic Memory Outpace Disease Pathogenesis?
- (2009) M. E. Pichichero PEDIATRICS
- Persistent Human Papillomavirus Infection and Cervical Neoplasia: A Systematic Review and Meta-Analysis
- (2008) J. Koshiol et al. AMERICAN JOURNAL OF EPIDEMIOLOGY
- HPV and cervical cancer: screening or vaccination?
- (2008) F X Bosch et al. BRITISH JOURNAL OF CANCER
- Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening
- (2008) V M H Coupé et al. BRITISH JOURNAL OF CANCER
- A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: Importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention
- (2008) David Jenkins GYNECOLOGIC ONCOLOGY
- Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: Improving upon nature
- (2008) Tino F. Schwarz et al. GYNECOLOGIC ONCOLOGY
- Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Vaccine in Healthy Boys Aged 10–18 Years
- (2008) Tiina Petäjä et al. JOURNAL OF ADOLESCENT HEALTH
- Epidemiology and Natural History of Human Papillomavirus Infections and Type-Specific Implications in Cervical Neoplasia
- (2008) F. Xavier Bosch et al. VACCINE
- Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines
- (2008) Thomas Verstraeten et al. VACCINE
- An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results
- (2008) John T. Schiller et al. VACCINE
- Epidemiology of Human Papillomavirus Infection in Men, Cancers other than Cervical and Benign Conditions
- (2008) Anna R. Giuliano et al. VACCINE
- Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15–55 years
- (2008) Tino F. Schwarz et al. VACCINE
- HPV vaccines: peering through the fog
- (2008) Anne Szarewski JOURNAL OF FAMILY PLANNING AND REPRODUCTIVE HEALTH CARE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now